Enteropeptidase: a gene associated with a starvation human phenotype and a novel target for obesity treatment.

Enteropeptidase: a gene associated with a starvation human phenotype and a novel target for obesity treatment.

Blog Article

BACKGROUND: Obesity research focuses essentially on gene targets associated with the obese phenotype.None of these targets have yet provided a viable drug therapy.Focusing instead on genes that are involved in energy absorption and that are associated with a "human starvation phenotype", we have identified enteropeptidase (EP), a gene associated with congenital enteropeptidase deficiency, as a novel target Sta-Rite Max-E-Pro Parts for obesity treatment.

The advantages of this target are that the gene is expressed exclusively in the brush border of the intestine; it is peripheral and not redundant.METHODOLOGY/PRINCIPAL FINDINGS: Potent and selective EP inhibitors were designed around a boroarginine or borolysine motif.Oral administration of these compounds to mice restricted the bioavailability of dietary energy, and in a long-term treatment it significantly diminished the rate of increase in body weight, despite ad libitum food intake.

No adverse reactions of the type seen with lipase inhibitors, such RCA/AV Cables as diarrhea or steatorrhea, were observed.This validates EP as a novel, druggable target for obesity treatment.CONCLUSIONS: In vivo testing of novel boroarginine or borolysine-based EP inhibitors validates a novel approach to the treatment of obesity.